Key Points
- Director Karen Wilson bought 10,000 shares of Serina Therapeutics at $1.77 per share, totaling $17,700, according to an SEC filing.
- The purchase came as SER stock fell 3% and was trading at $1.92, leaving the company with a market cap of about $28.8 million.
- Serina Therapeutics recently reported a quarterly EPS of -$0.58 and continues developing treatments for neurological diseases and pain, including its lead candidate SER 252 for Parkinson’s disease.
Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) Director Karen Wilson bought 10,000 shares of Serina Therapeutics stock in a transaction on Thursday, May 21st. The shares were acquired at an average price of $1.77 per share, for a total transaction of $17,700.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $17,700. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Serina Therapeutics Stock Down 3.0%
Serina Therapeutics stock opened at $1.92 on Wednesday. The firm has a market cap of $28.80 million, a price-to-earnings ratio of -0.96 and a beta of 1.15. Serina Therapeutics, Inc. has a 52-week low of $1.22 and a 52-week high of $7.92. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The business's 50 day simple moving average is $1.96.
Serina Therapeutics (NYSEAMERICAN:SER - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.
Serina Therapeutics Company Profile
(
Get Free Report)
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
